Brain CommunicationsGenetic & Genomic MedicinePeer-reviewed journal article
Lack of Epistatic Interaction of SNCA with APOE in Synucleinopathies
Prabhjyot Saini, Eric YuiD, Mehrdad A. EstiariD, Lynne KrohniD, Kheireddin MuftiiD, Uladzislau RudakouiD, Jennifer A. RuskeyiD, Farnaz AsayeshiD, Sandra B. Laurent, Dan SpiegelmaniD, Isabelle ArnulfiD, Jacques Yves MontplaisiriD, Jean‐François GagnoniD, Alex DésautelsiD, Yves A DauvilliersiD, Gian Luigi GigliiD, Mariarosaria ValenteiD, Francesco JanesiD, Andrea BernardiniiD, Karel ŠonkaiD, David KemlinkiD, Wolfgang Hermann OerteliD, Karri KaivolaiD, Annette JanzeniD, Giuseppe PlazziiD, , Ziv Gan‐OriD
Abstract
Two recent studies suggested that the APOE {varepsilon}4 haplotype was associated with increased -synuclein pathology in cell and mouse models. Genetic variants in the SNCA region have strong association with Parkinsons disease (PD), Dementia with Lewy Bodies (DLB), and idiopathic REM Sleep Behavior Disorder (iRBD), while APOE is a genetic risk determinant for only DLB. To determine if genetic-level interactions between SNCA and APOE exists that can explain the protein-level association, we investigated the genotypic interaction of APOE and SNCA in cohorts of PD, DLB, and iRBD. We analyzed genome-wide association study (GWAS) data from 5,229 PD patients and 5,480 controls, 2,610 DLB patients and 1,920 controls, and 1,055 iRBD patients and 3,667 controls. We used logistic regression interaction models across all 3 cohorts independently between the 1) top GWAS signals of SNCA SNPs and APOE haplotypes, 2) SNP x SNP and 3-way SNP interaction across the entire coding region plus 200kb flanking each gene. No significant interactions were found to be associated with any of the synucleinopathies after correction for multiple testing. Our results do not support a role for genetic interactions between APOE and SNCA across PD, DLB, and iRBD. Since the tested genetic variants affect the expression and function of these proteins, it is likely that any interactions between them does not affect the risk of PD, DLB and iRBD.
- organism: human
- assay: GWAS summary statistics
- research focus: gene regulatory network inference
- approach: statistical model
- Citations
- 1
- FWCI
- 0.61
- Field percentile
- top 28%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Genome-wide association study of REM sleep behavior disorder in Parkinson's disease
Yuri Ludwig Sosero, Karl Heilbron, … Ziv Gan‐Or·npj Parkinson s DiseasePeer-reviewed·Sep 25, 2025
- Genetic Modifiers of Age at Onset for Parkinson's Disease in European Populations
the Global Parkinson’s Genetic Program (GP2), Erin R. Voss·medRxiv·Oct 26, 2026
- Genome-wide association, Mendelian Randomization and polygenic risk score studies converge on a role of beta-amyloid and APOE locus in Parkinson disease
Laura Ibáñez, Jorge Alberto Bahena, … Bruno A. Benítez·Acta Neuropathologica CommunicationsPeer-reviewed·Nov 19, 2020
- Fine-mapping of SNCA in REM sleep behavior disorder and overt synucleinopathies
Lynne Krohn, Richard Y. J. Wu, … Ziv Gan‐Or·Annals of NeurologyPeer-reviewed·Jan 24, 2020
- Parkinson disease age of onset GWAS: defining heritability, genetic loci and a-synuclein mechanisms
Cornelis Blauwendraat, Karl Heilbron, … Andrew Singleton·Movement DisordersPeer-reviewed·Apr 7, 2019
- Lack of genetic evidence for a role of SLC25A46 in alpha-synucleinopathies
Han Yu, Sitki Cem Parlar, … Ziv Gan‐Or·Journal of Parkinson s DiseasePeer-reviewed·Aug 6, 2026